DLL4 and non-small cell squamous lung carcinoma: Demcizumab is a humanized immunoglobulin G2 antibody that binds to Delta-Like Ligand 4 (Drosophila, DLL4), and is being studied in an ongoing phase 1b dose escalation study in combination with pemetrexed and carboplatin in chemotherapy-naïve stage IIIb/IV non-squamous non-small cell lung cancer.198